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ABSTRACT
Background: Cardiogenic shock is a clinical condition of 
inadequate tissue perfusion due to cardiac dysfunction. The 
most common etiology is ST-segment elevation myocardial 
infarction (STEMI) leading to left ventricular failure, but it may 
also be caused by mechanical complications such as acute 
mitral regurgitation, ventricular septal rupture or rupture of the 
left ventricular free wall. Despite therapeutic advances, mortal-
ity rates remain high. Methods: Retrospective, observational, 
single-center study, including consecutive patients admitted 
with a diagnosis of STEMI and cardiogenic shock treated by 
percutaneous coronary intervention (PCI) at a tertiary hospital 
specialized in cardiology. The primary objective was to evaluate 
in-hospital clinical outcomes. Results: A total of 78 patients 
were included, most of them were male (67.9%), mean age 
was 67.5 ± 13,4 years and 41.0% were diabetic. Primary PCI 
was performed in 46.2% of the patients, rescue PCI in 25.6% 
and elective PCI in 28.2% of the cases. The most frequently 
involved arteries were the left anterior descending artery and 
the right coronary artery, with 44.9% each. Intra-aortic bal-
loon pump was used in 32.1% of cases and glycoprotein IIb/
IIIa inhibitors in 30.8% of the cases. The incidence of acute 
renal failure was 61.5%. The need for reintervention was 
observed in 9.0% and the rate of acute/subacute thrombosis 
was 3.8%. Death due to cardiogenic shock was observed in 
46.2%. Conclusions: Cardiogenic shock remains a frequent 
and serious condition with almost 50% of in-hospital mortality 
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RESUMO
Evolução Hospitalar de Pacientes com Choque 
Cardiogênico por Infarto Agudo do Miocárdio com 
Supradesnivelamento do Segmento ST
Introdução: O choque cardiogênico é uma condição clínica 
de inadequada perfusão tecidual devido à disfunção cardíaca. 
A etiologia mais comum é o infarto agudo do miocárdio com 
elevação do segmento ST (IMCSST) levando à insuficiência 
ventricular esquerda, mas também pode ser causado por com-
plicações mecânicas, como insuficiência mitral aguda, ruptura 
do septo interventricular ou da parede livre do ventrículo 
esquerdo. Apesar dos avanços terapêuticos, a mortalidade 
continua elevada. Métodos: Estudo retrospectivo, observacional, 
unicêntrico, incluindo pacientes consecutivos internados com 
o diagnóstico de IMCSST e choque cardiogênico, tratados por 
intervenção coronária percutânea (ICP), em hospital terciário 
especializado em cardiologia. O objetivo primário foi avaliar 
os desfechos clínicos hospitalares. Resultados: Foram incluídos 
78 pacientes, a maioria do sexo masculino (67,9%), com 
idade de 67,5 ± 13,4 anos e 41,0% diabéticos. ICP primária 
foi realizada em 46,2% dos pacientes, ICP de resgate em 
25,6% e ICP eletiva em 28,2% dos casos. As artérias mais 
frequentemente acometidas foram a descendente anterior e a 
coronária direita, com 44,9% cada uma. O balão intra-aórtico 
foi utilizado em 32,1% e os inibidores da glicoproteína IIb/
IIIa em 30,8% dos casos. A incidência de insuficiência renal 
aguda foi de 61,5%. A necessidade de reintervenção ocorreu 
em 9,0%, e a taxa de trombose aguda/subaguda foi de 3,8%. 
Óbito, no choque cardiogênico, ocorreu em 46,2%. Conclusões: 
O choque cardiogênico permanece uma entidade frequente e 
grave, com quase 50% de mortalidade hospitalar, apesar da 
evolução na terapêutica instituída atualmente.
DESCRITORES: Choque cardiogênico. Infarto do miocárdio. 
Intervenção coronária percutânea. Balão intra-aórtico.
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São Paulo (Incor/HCFMUSP) in São Paulo, SP, Brazil, 
from January 2008 to March 2011. This study included 
all patients who developed cardiogenic shock during 
hospitalization and who were treated by PCI (primary, 
rescue, or elective).
Data collection and analysis
The in-hospital evolution data were collected by 
trained physicians, during the index hospitalization, 
following the completion of previously standardized 
forms. The data collected included clinical features, 
laboratory test results, percutaneous procedure data, 
and clinical outcome until hospital discharge.
Definitions
STEMI was diagnosed upon the occurrence of per-
sistent ST elevation > 1 mm in two contiguous leads or 
new left bundle branch block inthe electrocardiogram. 
Cardiogenic shock was defined by clinical criteria, 
according to the Should We Emergently Revascularize 
Occluded Coronaries for Cardiogenic Shock (SHOCK) 
trial, considering the presence of hypotension (systolic 
blood pressure < 90 mmHg for at least 30 minutes or 
requiring supportive measures to maintain systolic blood 
pressure > 90 mmHg) and organic hypoperfusion (urine 
output < 30 mL/minute and heart rate > 60 bpm).8
Acute renal failure was considered as a 25% in-
crease in baseline serum creatinine, or absolute increase 
of 0.5 mg/dL in serum creatinine between two and 
seven days after procedure completion.12 The evalu-
ated vascular complications were pseudo aneurysm, 
arteriovenous fistula, hematoma at the access site (> 
10 cm), distal embolization and/or ischaemia related 
to the puncture site, and bleeding at the access site, 
defined as a decrease in hemoglobin > 2 g/dL or one 
requiring transfusion. Death was defined as death from 
any cause.11
Continuous variables were represented as means 
and standard deviations, and categorical variables as 
absolute numbers and percentages.
RESULTS
Of a total of 513 patients diagnosed with STEMI, 
78 (15.2 %) had cardiogenic shock. The clinical char-
acteristics of the included patients are summarized in 
Table 1. The majority were male (67.9 %) with mean 
age of 67.5 ± 13.4 years. Diabetes was present in 
41.0% of patients and 9% used insulin. Prior PCI had 
been performed in 16.7% of patients and 7.7% had 
undergone previous CABG. Chronic renal failure and 
peripheral vascular insufficiency were present in 15.4% 
and 10.3% of patients, respectively.
Regarding the reperfusion therapy, 46.2% of patients 
underwent primary, 25.6% rescue, and 28.2% elective 
PCI. Left anterior descending artery and right coronary 
C ardiogenic shock is a clinical condition of inad-equate tissue perfusion due to cardiac dysfunction. Its definition includes the following hemodynamic 
parameters: persistent hypotension (systolic pressure < 80 
to 90 mmHg or mean blood pressure 30 mmHg lower 
than mean baseline blood pressure), with a marked 
reduction in cardiac index (< 1.8 L/min per m², without 
hemodynamic support, or  < 2.0 to 2.2  L/min per m² 
with hemodynamic support) and normal or elevated 
ventricular filling pressures. The most common etiology 
of cardiogenic shock isST-segment elevation myocardial 
infarction (STEMI), leading to left ventricular failure, 
but it can also be caused by mechanical complica-
tions, such as acute mitral regurgitation, or rupture of 
the interventricular septum or left ventricular free wall. 
However, any cause of severe acute ventricular dysfunc-
tion, either right or left, can lead to cardiogenic shock.1
The prevalence of cardiogenic shock appears to 
be decreasing since the mid-1970s. In a report from 
a metropolitan area in the United States (Worcester, 
Massachusetts), the incidence of cardiogenic shock was 
7% between 1975 and 1990, decreasing to 5.5% to 
6.0% since then.2 This improvement in the incidence 
of cardiogenic shock and associated mortality partly 
reflects the increasein the use of coronary reperfusion 
strategies, which, through correction of the infarct-related 
arterial patency, may limit the extentof the infarction.3-5
In this context, the mortality rates are still high, 
ranging in the most recent studies from 42% to 
48%.2,6,7 Temporal analysis demonstrated a reduction 
in this outcome between the years 1995 and 2004 
(60.3%vs. 47.9%; P < 0.001), mainly associated with 
the performance of early percutaneous coronary inter-
vention (PCI), with the most evident benefit during the 
in-hospital period.2 This concept is important because, 
although studies have shown no differences between 
the mortality rates in relation to the chosen method of 
revascularization,8 in clinical practice more than 60% 
of patients admitted with STEMI and cardiogenic shock 
are treated by early PCI, with emergency coronary 
artery bypass graft (CABG) surgery performed in less 
than 5% of cases.
There have been few studies carried out in the 
Brazilian population admitted with STEMI, and the data 
related to cardiogenic shock were obtained from small 
subgroups.8-11 Thus, the present work aimed to evalu-
ate the short-term hospital evolution and outcomes of 




This study evaluated patients with STEMI who 
underwent PCI at Instituto do Coração do Hospital das 
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arteries were each the culprit arteries of STEMI in 44.9 
% of patients. The intra-aortic balloon was used in 
32.1% of cases, and glycoprotein IIb/IIIa inhibitors in 
30.8% of cases.
Clinical outcomes and in-hospital complications are 
shown in Table 2. The main complication associated 
with cardiogenic shock was the development of acute 
renal failure, which occurred in 61.5% of cases. The 
need for re-intervention occurred in 9.0% of the cases 
and the rate of acute/subacute thrombosis was 3.8%. 
The death rate from cardiogenic shock was 46.2%.
DISCUSSION
Cardiogenic shock is the leading cause of death 
for patients admitted with STEMI and, despite treatment 
advances in recent years, including early revasculariza-
tion through PCI or CABG, as well as the use of potent 
anticoagulant and antiplatelet agents, the mortality rates 
remain high.
Despite the high mortality rate observed in this 
study, it is very close to that reported in the literature, 
described as between 42% and 65% of patients, es-
pecially when the intra-aortic balloon was indicated 
during PCI with established cardiogenic shock.13-15 In 
a sub-analysis of the American National Registry of 
Myocardial Infarction 2 (NRMI-2),16 the mortality rate 
from AMI complicated by cardiogenic shock, even in 
hospitals with extensive use of intra-aortic balloon, 
was 50.6%,versus 65.4% in hospitals with lower rates 
of use of this circulatory support device (P <  0.001).
The decrease of mortality in cardiogenic shock is 
related to achieving successful recanalization of the 
culprit vessel. In the SHOCK trial,8 a mortality rate of 
39% was demonstrated in successfully treated cases, 
and a rate of 85% in cases thatdid not attain procedural 
success. All patients with TIMI flow 0 or 1 at the end 
TABLE 1  
Clinical, angiographic and procedural characteristics 
Characteristics n = 78
Age, years 64.5 ± 13.4
Male gender, n (%) 53 (67.9)
Arterial hypertension, n (%) 65 (83.3)
Dyslipidemia, n (%) 67 (85.9)
Statin use 44 (56.4)
Diabetes mellitus, n (%) 32 (41.0)
Insulin use 7 (9.0)
Smoking, n (%)
Never 30 (38.5)
Stopped < 1 year 2 (2.5)
Stopped > 1 year 14 (17.9)
Current smoker 32 (41.0)
Family history of CAD, n (%) 12 (15.4)
Previous stroke, n (%) 3 (3.9)
Previous PCI, n (%) 13 (16.7)
Previous CABG, n (%) 6 (7.7)
COPD, n (%) 6 (7.7)
Hypothyroidism, n (%) 4 (5.1)
Chronic renal failure, n (%) 12 (15.4)
Renal transplantation, n (%) 1 (1.3)
Peripheral vascular failure, n (%) 8 (10.3)
Congestive heart failure, n (%) 18 (23.1)
Cocaine use, n (%) 1 (1.3)
Primary PCI, n (%) 36 (46.2)
Rescue PCI, n (%) 20 (25.6)
Elective PCI, n (%) 22 (28.2)
Infarct location, n (%)
Anterior 35 (44.9)





Culprit artery, n (%)
Left anterior descending artery 35 (44.9)
Left circumflex artery 8 (10.2)
Right coronary 35 (44.9)
Intra-aortic balloon use, n (%) 25 (32.1)
GPI IIb/IIIa use, n (%) 24 (30.8)
CAD = coronary artery disease; PCI = percutaneous coronary 
intervention; CABG = coronary-artery bypass grafting; COPD 
= chronic obstructive pulmonary disease; GPI = glycoprotein 
inhibitors.
TABLE 2  
Clinical outcomes and in-hospital complications
Events n = 78
Death, n (%) 36 (46.2)
Stroke, n (%) 1 (1.3)
Re-intervention, n (%) 7 (9.0)
Acute/subacute stent thrombosis, n (%) 3 (3.8)
Bleeding, n (%) 4 (5.1)
Blood transfusion, n (%) 7 (9.0)
Acute pulmonary oedema, n (%) 33 (42.3)
Vascular surgery, n (%) 1 (1.3)
Acute renal failure, n (%) 48 (61.5)
Hemodialysis, n (%) 12 (15.4)
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of the intervention progressed to death. In the late six-
year follow-up, the early reperfusion strategy showed a 
relative reduction in mortality of 67%, in comparison 
with the initial clinical compensation strategy.12 Another 
recent clinical trial, comparing mortality throughout 
35 years of evolution of cardiogenic shock treatment, 
showed a significant reduction in mortality rates over-
time (76% in 1980s, 65.6 % in the 1990s, and 42% 
since 2000), which are similar values to those found 
in this study’s population.17
Study limitations
Among the limitations of the present study are its 
observational design and lack of control group. The 
lack of appropriate time of ischaemia assessment is 
also highlighted. This was due to the fact that many 
patients were transferred directly from other peripheral 
healthcare network services to undergo PCI, which 
limited the appropriate evaluation of the pain-to-door 
and door-to-balloon time, once the data were ob-
tained from medical records and, in many cases, this 
information was not obtained. These pain-to-door and 
door-to-balloon time variables could provide further 
information, as both were significantly correlated with 
the mortality rate in the literature.8,18,19
CONCLUSIONS
Cardiogenic shock remains a frequent and severe 
entity, with mortality rates of approximately 50% 
despite the currently established therapy. Therefore, 
it is observed that the best strategy would be the 
prevention of acute coronary events and, when they 
occur, early myocardial reperfusion measures should 
be attempted to prevent circulatory collapse and its 
unfavorable consequences.
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